Downstaging as a direct patient benefit in cancer screening
Journal of Medical Screening · 2026-12 · 33 (4) · 264-271
DOI: 10.1177/09691413261473145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Screening, online erschienen am 31.07.2026. Verfasst von Paul F Pinsky und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Early Detection of Cancer, Lung Neoplasms. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
The standard metric to assess the benefit of cancer screening is reduction in cancer-specific mortality. However, patients may benefit from downstaging of disease due to screening, even among those who would have survived late-stage disease absent screening.
Methods
We developed a model of stage and survival in the absence and presence of screening. Within each stage/survival category without screening, there are transition probabilities to various stage/survival and mode of detection (screen detected or not) categories under screening. The model includes rules for allowable transitions; for example, stage and survival are unchanged for non-screen detected cancers, and survival status changing from dying to surviving requires downstaging. A two-stage (early/late) model was fit to National Lung Screening Trial (NLST) data. The low-dose computed tomography (LDCT) arm was considered the screening arm and the chest radiograph arm the control (non-screening) arm.
Results
There were 1032 and 993 lung cancer cases in the NLST LDCT and control arm, respectively. 15.2% of control arm cases were late-stage (III/IV) survivors. Their rate of transitioning to early-stage (I/II) survivors under screening was 18.4%, resulting in 2.8% (15.2% * 18.4%) of all cases transitioning from late-stage survivors under no screening to early-stage survivors with screening. 47.1% of late-stage control arm cases did not survive; their rate of transitioning to early-stage survivors under screening was 21.5%, resulting in 10.1% (47.1% * 21.5%) of all cases under no screening with that transition.
Conclusions
Modeling the effects of screening on stage and survival can help elucidate a more holistic set of screening benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
ORCID-Profile: Paul F Pinsky
Zitieren
APA
Pinsky, P. F., LeeVan, E. M., Rubinstein, W. S., Patriotis, C., & Minasian, L. (2026). Downstaging as a direct patient benefit in cancer screening. Journal of Medical Screening, 33(4), 264-271. https://doi.org/10.1177/09691413261473145
Vancouver
Pinsky PF, LeeVan EM, Rubinstein WS, Patriotis C, Minasian L. Downstaging as a direct patient benefit in cancer screening. Journal of Medical Screening. 2026;33(4):264-271. doi:10.1177/09691413261473145
BibTeX
@article{Pinsky2026,
author = {Pinsky, Paul F and LeeVan, Elyse M and Rubinstein, Wendy S and Patriotis, Christos and Minasian, Lori},
title = {Downstaging as a direct patient benefit in cancer screening},
journal = {Journal of Medical Screening},
year = {2026},
volume = {33},
number = {4},
pages = {264--271},
doi = {10.1177/09691413261473145}
}
EUVIMED